^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DR-01

    i
    Other names: DR-01
    Associations

    News

    Trials
    Company:
    Dren Bio
    Drug class:
    CD94 inhibitor
    Associations

    News

    Trials
    4ms
    A Study of Subcutaneous DR-01 in Healthy Volunteers (clinicaltrials.gov)
    P1, N=32, Completed, Dren Bio | Active, not recruiting --> Completed
    Trial completion
    |
    DR-01
    6ms
    A Study of Subcutaneous DR-01 in Healthy Volunteers (clinicaltrials.gov)
    P1, N=32, Active, not recruiting, Dren Bio | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    DR-01
    11ms
    A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo (clinicaltrials.gov)
    P1, N=80, Recruiting, Dren Bio | N=60 --> 80
    Enrollment change
    |
    DR-01
    1year
    A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas (clinicaltrials.gov)
    P1/2, N=69, Recruiting, Dren Bio | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    DR-01
    1year
    A Study of Subcutaneous DR-01 in Healthy Volunteers (clinicaltrials.gov)
    P1, N=36, Recruiting, Dren Bio | Not yet recruiting --> Recruiting
    Enrollment open
    |
    DR-01
    1year
    A Study of Subcutaneous DR-01 in Healthy Volunteers (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Dren Bio
    New P1 trial
    |
    DR-01
    over1year
    A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo (clinicaltrials.gov)
    P1, N=60, Recruiting, Dren Bio | Not yet recruiting --> Recruiting
    Enrollment open
    |
    DR-01
    over1year
    A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, Dren Bio
    New P1 trial
    |
    DR-01
    over3years
    DR-01, a Non-Fucosylated Anti-CD94 Antibody, Depletes Leukemic Cells in Ex Vivo and In Vivo Models of Large Granular Lymphocyte Leukemia (ASH 2022)
    In addition, treatments are limited to standard immunosuppressive therapy such as methotrexate, cyclosporine or cyclophosphamide, with complete response rates of only 50% or less for each agent. Additional profiling and evaluation of DR-01 in LGLL patient samples ex vivo as part of a pre-phase I study is ongoing. A phase I/II trial has been initiated to assess the safety and efficacy of DR-01 in previously treated LGLL patients.
    Preclinical
    |
    CD8 (cluster of differentiation 8) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • LAMP1 (Lysosomal Associated Membrane Protein 1) • FCGR3A (Fc Fragment Of IgG Receptor IIIa) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1) • KLRC1 (Killer Cell Lectin Like Receptor C1)
    |
    cyclophosphamide • methotrexate • cyclosporine • DR-01